Active Pharmaceutical Ingredients CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Molecule Type, By Synthesis, By Drug Type, By Workflow, By Application, By Region and Competition, 2020-2030F

Description

The Global Active Pharmaceutical Ingredients CDMO Market, valued at USD 96.98 Million in 2024, is projected to experience a CAGR of 6.1% to reach USD 138.35 Million by 2030. An Active Pharmaceutical Ingredient (API) Contract Development and Manufacturing Organization (CDMO) provides comprehensive development and manufacturing services for APIs on a contract basis, assisting pharmaceutical firms with drug substance synthesis, process optimization, scalable production, and regulatory compliance. The market's growth is primarily driven by increasing pharmaceutical research and development investments, the escalating global prevalence of chronic diseases necessitating new therapies, and the growing complexity of drug molecules.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 96.98 Million
Market Size 2030	USD 138.35 Million
CAGR 2025-2030	6.1%
Fastest Growing Segment	Oncology
Largest Market	North America

Key Market Drivers

The robust pharmaceutical research and development pipeline, along with consistent new drug approvals, significantly drives the Global Active Pharmaceutical Ingredients CDMO Market. Substantial industry investment in novel therapies necessitates specialized API development and manufacturing expertise. According to the International Federation of Pharmaceutical Manufacturers & Associations, global pharmaceutical R&D expenditure reached USD 204 billion in 2023, underscoring this commitment to innovation and growth. This sustained investment fuels demand for CDMOs capable of supporting complex early-stage development through commercial scale production. The global API manufacturing landscape features geographically diversified capabilities, crucial for supply chain resilience. For instance, according to the Pacific Forum, in 2022, India housed 18% of global API manufacturing facilities, demonstrating the importance of specialized centers in meeting worldwide demand.

Key Market Challenges

A significant challenge impeding the growth of the Global Active Pharmaceutical Ingredients CDMO Market involves maintaining adequate transparency and control over outsourced production processes. This difficulty can lead to struggles in pinpointing the origin of manufacturing issues, navigating complex supply chains, and potentially causing a loss of critical knowledge for the contracting pharmaceutical company. Without clear visibility and stringent control, pharmaceutical firms face heightened risks regarding product quality and regulatory compliance.

Key Market Trends

The rising outsourcing of biologics and advanced therapies production represents a pivotal trend in the Global Active Pharmaceutical Ingredients CDMO Market. As pharmaceutical companies increasingly focus on complex biopharmaceuticals, including monoclonal antibodies, cell, and gene therapies, the specialized expertise and infrastructure required for their development and manufacturing often necessitate external partnerships. These advanced modalities demand sophisticated facilities, stringent quality control, and specialized technical personnel that many pharmaceutical companies prefer to outsource to dedicated CDMOs. The U. S. Food and Drug Administration (FDA) reported that in 2023, the Center for Biologics Evaluation and Research (CBER) approved 22 new Biologics License Applications (BLAs), nearly doubling the approvals from 2021 and 2022, underscoring the expanding pipeline in this segment.

Key Market Players

Cambrex Corporation
Thermo Fisher Scientific, Inc.
Recipharm AB
Corden Pharma International GmbH
Samsung Biologics Co., Ltd.
Lonza Group Ltd.
Siegfried Holding AG
Piramal Pharma Limited
AbbVie Inc.
Catalent, Inc.

Report Scope:

In this report, the Global Active Pharmaceutical Ingredients CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Active Pharmaceutical Ingredients CDMO Market, By Molecule Type:

Small Molecule
Large Molecule

Active Pharmaceutical Ingredients CDMO Market, By Synthesis:

Biotech
Synthetic

Active Pharmaceutical Ingredients CDMO Market, By Drug Type:

Innovative
Generics

Active Pharmaceutical Ingredients CDMO Market, By Workflow:

Clinical
Commercial

Active Pharmaceutical Ingredients CDMO Market, By Application:

Cardiology
Oncology
Ophthalmology
Neurology
Orthopedic
Other

Active Pharmaceutical Ingredients CDMO Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Active Pharmaceutical Ingredients CDMO Market.

Available Customizations:

Global Active Pharmaceutical Ingredients CDMO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Active Pharmaceutical Ingredients CDMO Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Molecule Type (Small Molecule, Large Molecule)
- 5.2.2. By Synthesis (Biotech, Synthetic)
- 5.2.3. By Drug Type (Innovative, Generics)
- 5.2.4. By Workflow (Clinical, Commercial)
- 5.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
- 5.2.6. By Region
- 5.2.7. By Company (2024)
5.3. Market Map

6. North America Active Pharmaceutical Ingredients CDMO Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Molecule Type
- 6.2.2. By Synthesis
- 6.2.3. By Drug Type
- 6.2.4. By Workflow
- 6.2.5. By Application
- 6.2.6. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Active Pharmaceutical Ingredients CDMO Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Molecule Type
    - 6.3.1.2.2. By Synthesis
    - 6.3.1.2.3. By Drug Type
    - 6.3.1.2.4. By Workflow
    - 6.3.1.2.5. By Application
- 6.3.2. Canada Active Pharmaceutical Ingredients CDMO Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Molecule Type
    - 6.3.2.2.2. By Synthesis
    - 6.3.2.2.3. By Drug Type
    - 6.3.2.2.4. By Workflow
    - 6.3.2.2.5. By Application
- 6.3.3. Mexico Active Pharmaceutical Ingredients CDMO Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Molecule Type
    - 6.3.3.2.2. By Synthesis
    - 6.3.3.2.3. By Drug Type
    - 6.3.3.2.4. By Workflow
    - 6.3.3.2.5. By Application

7. Europe Active Pharmaceutical Ingredients CDMO Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Molecule Type
- 7.2.2. By Synthesis
- 7.2.3. By Drug Type
- 7.2.4. By Workflow
- 7.2.5. By Application
- 7.2.6. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Active Pharmaceutical Ingredients CDMO Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Molecule Type
    - 7.3.1.2.2. By Synthesis
    - 7.3.1.2.3. By Drug Type
    - 7.3.1.2.4. By Workflow
    - 7.3.1.2.5. By Application
- 7.3.2. France Active Pharmaceutical Ingredients CDMO Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Molecule Type
    - 7.3.2.2.2. By Synthesis
    - 7.3.2.2.3. By Drug Type
    - 7.3.2.2.4. By Workflow
    - 7.3.2.2.5. By Application
- 7.3.3. United Kingdom Active Pharmaceutical Ingredients CDMO Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Molecule Type
    - 7.3.3.2.2. By Synthesis
    - 7.3.3.2.3. By Drug Type
    - 7.3.3.2.4. By Workflow
    - 7.3.3.2.5. By Application
- 7.3.4. Italy Active Pharmaceutical Ingredients CDMO Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Molecule Type
    - 7.3.4.2.2. By Synthesis
    - 7.3.4.2.3. By Drug Type
    - 7.3.4.2.4. By Workflow
    - 7.3.4.2.5. By Application
- 7.3.5. Spain Active Pharmaceutical Ingredients CDMO Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Molecule Type
    - 7.3.5.2.2. By Synthesis
    - 7.3.5.2.3. By Drug Type
    - 7.3.5.2.4. By Workflow
    - 7.3.5.2.5. By Application

8. Asia Pacific Active Pharmaceutical Ingredients CDMO Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Molecule Type
- 8.2.2. By Synthesis
- 8.2.3. By Drug Type
- 8.2.4. By Workflow
- 8.2.5. By Application
- 8.2.6. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Active Pharmaceutical Ingredients CDMO Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Molecule Type
    - 8.3.1.2.2. By Synthesis
    - 8.3.1.2.3. By Drug Type
    - 8.3.1.2.4. By Workflow
    - 8.3.1.2.5. By Application
- 8.3.2. India Active Pharmaceutical Ingredients CDMO Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Molecule Type
    - 8.3.2.2.2. By Synthesis
    - 8.3.2.2.3. By Drug Type
    - 8.3.2.2.4. By Workflow
    - 8.3.2.2.5. By Application
- 8.3.3. Japan Active Pharmaceutical Ingredients CDMO Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Molecule Type
    - 8.3.3.2.2. By Synthesis
    - 8.3.3.2.3. By Drug Type
    - 8.3.3.2.4. By Workflow
    - 8.3.3.2.5. By Application
- 8.3.4. South Korea Active Pharmaceutical Ingredients CDMO Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Molecule Type
    - 8.3.4.2.2. By Synthesis
    - 8.3.4.2.3. By Drug Type
    - 8.3.4.2.4. By Workflow
    - 8.3.4.2.5. By Application
- 8.3.5. Australia Active Pharmaceutical Ingredients CDMO Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Molecule Type
    - 8.3.5.2.2. By Synthesis
    - 8.3.5.2.3. By Drug Type
    - 8.3.5.2.4. By Workflow
    - 8.3.5.2.5. By Application

9. Middle East & Africa Active Pharmaceutical Ingredients CDMO Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Molecule Type
- 9.2.2. By Synthesis
- 9.2.3. By Drug Type
- 9.2.4. By Workflow
- 9.2.5. By Application
- 9.2.6. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Active Pharmaceutical Ingredients CDMO Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Molecule Type
    - 9.3.1.2.2. By Synthesis
    - 9.3.1.2.3. By Drug Type
    - 9.3.1.2.4. By Workflow
    - 9.3.1.2.5. By Application
- 9.3.2. UAE Active Pharmaceutical Ingredients CDMO Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Molecule Type
    - 9.3.2.2.2. By Synthesis
    - 9.3.2.2.3. By Drug Type
    - 9.3.2.2.4. By Workflow
    - 9.3.2.2.5. By Application
- 9.3.3. South Africa Active Pharmaceutical Ingredients CDMO Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Molecule Type
    - 9.3.3.2.2. By Synthesis
    - 9.3.3.2.3. By Drug Type
    - 9.3.3.2.4. By Workflow
    - 9.3.3.2.5. By Application

10. South America Active Pharmaceutical Ingredients CDMO Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Molecule Type
- 10.2.2. By Synthesis
- 10.2.3. By Drug Type
- 10.2.4. By Workflow
- 10.2.5. By Application
- 10.2.6. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Active Pharmaceutical Ingredients CDMO Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Molecule Type
    - 10.3.1.2.2. By Synthesis
    - 10.3.1.2.3. By Drug Type
    - 10.3.1.2.4. By Workflow
    - 10.3.1.2.5. By Application
- 10.3.2. Colombia Active Pharmaceutical Ingredients CDMO Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Molecule Type
    - 10.3.2.2.2. By Synthesis
    - 10.3.2.2.3. By Drug Type
    - 10.3.2.2.4. By Workflow
    - 10.3.2.2.5. By Application
- 10.3.3. Argentina Active Pharmaceutical Ingredients CDMO Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Molecule Type
    - 10.3.3.2.2. By Synthesis
    - 10.3.3.2.3. By Drug Type
    - 10.3.3.2.4. By Workflow
    - 10.3.3.2.5. By Application

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Active Pharmaceutical Ingredients CDMO Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Cambrex Corporation
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Thermo Fisher Scientific, Inc.
15.3. Recipharm AB
15.4. Corden Pharma International GmbH
15.5. Samsung Biologics Co., Ltd.
15.6. Lonza Group Ltd.
15.7. Siegfried Holding AG
15.8. Piramal Pharma Limited
15.9. AbbVie Inc.
15.10. Catalent, Inc.